Ozen, M. Et Al. 2016. Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients. JOURNAL OF BUON , vol.21, no.4 , 799-808.

Ozen, M., Gunduz, M., ATEŞ, Ö., BABACAN, T., SEVER, A. R., AKIN, S., ... Ozisik, Y.(2016). Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients. JOURNAL OF BUON , vol.21, no.4, 799-808.

Ozen, Mehmet Et Al. "Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients," JOURNAL OF BUON , vol.21, no.4, 799-808, 2016

Ozen, Mehmet Et Al. "Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients." JOURNAL OF BUON , vol.21, no.4, pp.799-808, 2016

Ozen, M. Et Al. (2016) . "Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients." JOURNAL OF BUON , vol.21, no.4, pp.799-808.

@article{article, author={Mehmet Ozen Et Al. }, title={Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients}, journal={JOURNAL OF BUON}, year=2016, pages={799-808} }